SEC Form 4 · accession 0001144204-16-108389
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip Md Et Al Frost
Director · 10% Owner
Period of report
Jun 13, 2016
Accepted (ET)
Jun 15, 2016 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Company Stock OptionF1 | $0.22 | Jun 13, 2016 | A | 78,409 | A | Jun 13, 2016 | Jun 13, 2026 | Common Stock | 78,409 | 78,409 | D |
Explanation of responses
- F1Such options were granted to Dr. Frost in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable.